HLB Inc. announced on Monday that it has appointed Yang Eun-young, former Chief Business Officer (CBO) of Cha Bio Group, as President of its Bio Business Development Division.
Yang will spearhead global technology exports, acquisitions, co-development initiatives, and strategic alliances centered on HLB Group’s key bio pipelines. She will also oversee the establishment of global partnerships and commercialization strategies crucial for market entry and revenue generation.
Yang, a pharmacist by training, graduated from Seoul National University’s College of Pharmacy. She holds pharmacy licenses in South Korea and three U.S. states: Colorado, Florida, and Michigan.
After gaining experience in product strategy and marketing at Roche Korea and Eli Lilly Korea, Yang worked as a pharmacist in U.S. hospitals and pharmacies, broadening her understanding of the global pharmaceutical market and clinical environments.
She later led global sales at Samsung Biologics, driving business development and expanding contracts with international pharmaceutical companies.
From 2022, Yang served as CBO and Vice President at Cha Bio Group, overseeing business development for key bio affiliates, including Cha Biotech, Cha Vaccine Research Institute, and CMG Pharmaceutical.
This strategic hire aims to boost the global commercialization potential of new drug pipelines across HLB’s affiliates and strengthen business strategies for post-approval market entry and revenue generation.
The timing is particularly crucial, with the U.S. Food and Drug Administration (FDA) approval scheduled for July for the ribociclib-camrelizumab combination therapy and September for liraglutide, underscoring the growing importance of robust business development strategies.
HLB Group views Yang as the ideal candidate to refine its key pipeline commercialization roadmap, given her extensive business development and global sales experience with major pharmaceutical companies and leading domestic biotech firms.
The ribociclib-camrelizumab combination therapy, which targets both angiogenesis inhibition and immune activation, is currently undergoing global clinical trials, primarily for liver cancer. Liraglutide, a next-generation anticancer agent targeting HER2 mutations, shows promise for patients resistant to existing treatments.
